title: Open-label salsalate for the treatment of pre-diabetes in people with schizophrenia.
authors.forename: William R
authors.initials: WR
authors.lastname: Keller
authors.forename: Bernard A
authors.initials: BA
authors.lastname: Fischer
authors.forename: Robert P
authors.initials: RP
authors.lastname: McMahon
authors.forename: Walter
authors.initials: W
authors.lastname: Meyer
authors.forename: Robert W
authors.initials: RW
authors.lastname: Buchanan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D016207:Cytokines / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D011236:Prediabetic State / Q000139:chemically induced*; D011569:Psychiatric Status Rating Scales; D012459:Salicylates / Q000009:adverse effects*; D012559:Schizophrenia / Q000188:drug therapy*; D014280:Triglycerides / Q000378:metabolism; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D006442:Glycated Hemoglobin; D012459:Salicylates; D014280:Triglycerides; C517652:hemoglobin A1c protein, human; C014182:salicylsalicylic acid